LAVAL, Quebec—Bausch Health Companies Inc. (NYSE/TSX: BHC) filed a registration statement with the Securities and Exchange Commission this week noting that the parent company had previously submitted registration statements related to the planned separation and/or spinoff of both its Bausch + Lomb eyecare business and its medical aesthetics group. The medical aesthetics group will carry the name Global Solta upon its spinoff and debut as a separate company. “BHC [on Sept. 13] announced that it has previously confidentially submitted draft registration statements on Form S-1 with the Securities and Exchange Commission relating to each of the B+L separation and the Solta IPO,” a Bausch Health 8K filing noted.

“The number of common shares to be offered and the price range for the proposed transactions have not yet been determined. The company continues to expect the Solta IPO and the B+L separation to be completed on previously communicated timelines, subject to market and other conditions.”
Bausch Health initially stated its intention to separate the B+L business in August 2020, as VMAIL reported.
The company has not yet set terms for either deal, but expects them to completed on previously communicated timelines of the fourth quarter of 2021 or first half of 2022, based on market conditions, the 8K filing stated.